secwatch.observer — SEC 8-K summary
======================================

Issuer:     Equillium, Inc. (EQ)
CIK:        0001746466
Form:       8-K
Filed at:   2024-03-25T23:59:59+00:00
Accession:  0001193125-24-076471
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Equillium reports $40.9M cash; EQ101 Phase 2 topline due Q2; Ono itolizumab option decision 2H 2024
--------------------------------------------------------------------------------

- Cash $40.9M at Dec 31, 2023; runway into 2H 2025.
- EQ101 Phase 2 alopecia areata enrollment complete; topline data Q2 2024.
- FY2023 revenue $36.1M (Ono partnership); net loss $13.3M vs $62.4M prior year.
- Ono option exercise for itolizumab expected 2H 2024; $33M exercise payment plus $101M milestones.
- Phase 3 EQUATOR aGVHD interim review expected Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746466/000119312524076471/0001193125-24-076471-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746466/000119312524076471/d813838d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-076471

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer